caa a22 4500 445357568 CHVBK 20180317142905.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1007/s10072-011-0657-6 doi (NATIONALLICENCE)springer-10.1007/s10072-011-0657-6 Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis [Elektronische Daten] [Cristina Sancricca, Marina Mora, Enzo Ricci, Pietro Tonali, Renato Mantegazza, Massimiliano Mirabella] Sporadic inclusion-body myositis (s-IBM) is a chronic progressive inflammatory myopathy leading to severe disability. It has been suggested that statins may benefit s-IBM patients based on their pleiotropic effects on autoimmunity and possible adverse influence of increased cholesterol on muscle pathological changes. We carried out a pilot, open-label trial to evaluate safety and tolerability of oral simvastatin in s-IBM patients. Fourteen patients were treated with 40mg of simvastatin over 12months. Primary outcome measures included the assessment tools proposed by International Myositis Outcome Assessment Collaborative Study group and the IBM-Functional Rating Scale. As additional data, we report the results obtained from muscle MRI, biopsy and oropharyngeal scintigraphy. Ten patients completed the trial and the treatment appeared safe and well tolerated. None of the patients showed a significant clinical improvement. Outcome measures used in this study proved to be valuable tools for global assessment of s-IBM patients. At present, we cannot recommend simvastatin as a treatment for s-IBM though our data may warrant a placebo-controlled study. Springer-Verlag, 2011 Sporadic inclusion-body myositis nationallicence Simvastatin nationallicence Pilot clinical trial nationallicence Sancricca Cristina Department of Neurosciences, Catholic University School of Medicine, Policlinico "A. Gemelli”, Largo A. Gemelli 8, 00168, Rome, Italy aut Mora Marina Istituto Nazionale Neurologico "Carlo Besta”, Milan, Italy aut Ricci Enzo Department of Neurosciences, Catholic University School of Medicine, Policlinico "A. Gemelli”, Largo A. Gemelli 8, 00168, Rome, Italy aut Tonali Pietro Department of Neurosciences, Catholic University School of Medicine, Policlinico "A. Gemelli”, Largo A. Gemelli 8, 00168, Rome, Italy aut Mantegazza Renato Istituto Nazionale Neurologico "Carlo Besta”, Milan, Italy aut Mirabella Massimiliano Department of Neurosciences, Catholic University School of Medicine, Policlinico "A. Gemelli”, Largo A. Gemelli 8, 00168, Rome, Italy aut Neurological Sciences Springer Milan 32/5(2011-10-01), 841-847 1590-1874 32:5<841 2011 32 10072 https://doi.org/10.1007/s10072-011-0657-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10072-011-0657-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sancricca Cristina Department of Neurosciences, Catholic University School of Medicine, Policlinico "A. Gemelli”, Largo A. Gemelli 8, 00168, Rome, Italy aut NATIONALLICENCE 700 1- Mora Marina Istituto Nazionale Neurologico "Carlo Besta”, Milan, Italy aut NATIONALLICENCE 700 1- Ricci Enzo Department of Neurosciences, Catholic University School of Medicine, Policlinico "A. Gemelli”, Largo A. Gemelli 8, 00168, Rome, Italy aut NATIONALLICENCE 700 1- Tonali Pietro Department of Neurosciences, Catholic University School of Medicine, Policlinico "A. Gemelli”, Largo A. Gemelli 8, 00168, Rome, Italy aut NATIONALLICENCE 700 1- Mantegazza Renato Istituto Nazionale Neurologico "Carlo Besta”, Milan, Italy aut NATIONALLICENCE 700 1- Mirabella Massimiliano Department of Neurosciences, Catholic University School of Medicine, Policlinico "A. Gemelli”, Largo A. Gemelli 8, 00168, Rome, Italy aut NATIONALLICENCE 773 0- Neurological Sciences Springer Milan 32/5(2011-10-01), 841-847 1590-1874 32:5<841 2011 32 10072 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer